544 related articles for article (PubMed ID: 29636108)
1. GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2.
Li S; Ma YM; Zheng PS; Zhang P
J Exp Clin Cancer Res; 2018 Apr; 37(1):80. PubMed ID: 29636108
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.
Zhao TC; Zhou ZH; Ju WT; Liang SY; Tang X; Zhu DW; Zhang ZY; Zhong LP
Cancer Sci; 2022 Feb; 113(2):478-488. PubMed ID: 34826159
[TBL] [Abstract][Full Text] [Related]
3. BMX/Etk promotes cell proliferation and tumorigenicity of cervical cancer cells through PI3K/AKT/mTOR and STAT3 pathways.
Li Y; Cui N; Zheng PS; Yang WT
Oncotarget; 2017 Jul; 8(30):49238-49252. PubMed ID: 28514765
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase.
Gesmundo I; Di Blasio L; Banfi D; Villanova T; Fanciulli A; Favaro E; Gamba G; Musuraca C; Rapa I; Volante M; Munegato S; Papotti M; Gontero P; Primo L; Ghigo E; Granata R
Cancer Lett; 2019 May; 449():252-262. PubMed ID: 30790678
[TBL] [Abstract][Full Text] [Related]
5. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
Joshi JP; Brown NE; Griner SE; Nahta R
Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
[TBL] [Abstract][Full Text] [Related]
6. ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins.
Bai L; Mao R; Wang J; Ding L; Jiang S; Gao C; Kang H; Chen X; Sun X; Xu J
Med Oncol; 2015 Mar; 32(3):57. PubMed ID: 25647783
[TBL] [Abstract][Full Text] [Related]
7. Folate receptor alpha is associated with cervical carcinogenesis and regulates cervical cancer cells growth by activating ERK1/2/c-Fos/c-Jun.
Liu C; Ding L; Bai L; Chen X; Kang H; Hou L; Wang J
Biochem Biophys Res Commun; 2017 Sep; 491(4):1083-1091. PubMed ID: 28782518
[TBL] [Abstract][Full Text] [Related]
8. Slug inhibits the proliferation and tumor formation of human cervical cancer cells by up-regulating the p21/p27 proteins and down-regulating the activity of the Wnt/β-catenin signaling pathway via the trans-suppression Akt1/p-Akt1 expression.
Cui N; Yang WT; Zheng PS
Oncotarget; 2016 May; 7(18):26152-67. PubMed ID: 27036045
[TBL] [Abstract][Full Text] [Related]
9. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
10. Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells.
Tsui KH; Hsu SY; Chung LC; Lin YH; Feng TH; Lee TY; Chang PL; Juang HH
Sci Rep; 2015 Aug; 5():12870. PubMed ID: 26249737
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Prasad SB; Yadav SS; Das M; Modi A; Kumari S; Pandey LK; Singh S; Pradhan S; Narayan G
Cell Oncol (Dordr); 2015 Jun; 38(3):215-25. PubMed ID: 25821107
[TBL] [Abstract][Full Text] [Related]
12. Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling.
Xu Q; Xu HX; Li JP; Wang S; Fu Z; Jia J; Wang L; Zhu ZF; Lu R; Yao Z
Oncotarget; 2017 Mar; 8(10):16972-16987. PubMed ID: 28199981
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.
Liu X; Li G
Int J Clin Exp Pathol; 2015; 8(9):10605-14. PubMed ID: 26617770
[TBL] [Abstract][Full Text] [Related]
15. Osteocalcin Induces Proliferation via Positive Activation of the PI3K/Akt, P38 MAPK Pathways and Promotes Differentiation Through Activation of the GPRC6A-ERK1/2 Pathway in C2C12 Myoblast Cells.
Liu S; Gao F; Wen L; Ouyang M; Wang Y; Wang Q; Luo L; Jian Z
Cell Physiol Biochem; 2017; 43(3):1100-1112. PubMed ID: 28977794
[TBL] [Abstract][Full Text] [Related]
16. Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation.
Liu Y; Hock JM; Sullivan C; Fang G; Cox AJ; Davis KT; Davis BH; Li X
J Cell Biochem; 2010 Dec; 111(6):1546-55. PubMed ID: 20862710
[TBL] [Abstract][Full Text] [Related]
17. ARHGAP17 suppresses tumor progression and up-regulates P21 and P27 expression via inhibiting PI3K/AKT signaling pathway in cervical cancer.
Guo Q; Xiong Y; Song Y; Hua K; Gao S
Gene; 2019 Apr; 692():9-16. PubMed ID: 30641218
[TBL] [Abstract][Full Text] [Related]
18. Growth Differentiation Factor 15 Promotes Progression of Esophageal Squamous Cell Carcinoma via TGF-β Type II Receptor Activation.
Okamoto M; Koma YI; Kodama T; Nishio M; Shigeoka M; Yokozaki H
Pathobiology; 2020; 87(2):100-113. PubMed ID: 31896114
[TBL] [Abstract][Full Text] [Related]
19. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion.
Griner SE; Joshi JP; Nahta R
Biochem Pharmacol; 2013 Jan; 85(1):46-58. PubMed ID: 23085437
[TBL] [Abstract][Full Text] [Related]
20. Sinodielide A exerts thermosensitizing effects and induces apoptosis and G2/M cell cycle arrest in DU145 human prostate cancer cells via the Ras/Raf/MAPK and PI3K/Akt signaling pathways.
Hatashita M; Taniguchi M; Baba K; Koshiba K; Sato T; Jujo Y; Suzuki R; Hayashi S
Int J Mol Med; 2014 Feb; 33(2):406-14. PubMed ID: 24285252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
